Explore the latest advancements in immunotherapies for T-cell lymphoma, addressing unique challenges and promising new ...

T-cell acute lymphoblastic leukemia (T-ALL) is a highly aggressive form of blood cancer that can occur in both children and ...

Capstan Therapeutics scientists demonstrate that lipid nanoparticles can engineer CAR T cells within the body without laboratory cell manufacturing and ex vivo expansion. The method using targeted ...

Current approved CAR T-cell therapy treatments rely on an ex vivo route, in which a patient’s T cells are removed, genetically engineered to target antigens, and put back into the patient.

Autoimmune diseases, such as multiple sclerosis (MS), inflammatory bowel disease (IBD), and rheumatoid arthritis (RA), affect ...

Antibody–siRNA conjugates (ARCs) are a type of promising drug modalities for cancer therapy. However, initial reports of ARCs present the gene knockdown effect only in limited tissues (e.g., muscles) ...

Fragile X disorders include two distinct conditions: fragile X syndrome (the most common single-gene cause of developmental ...

A team at the Peter Mac is planning for first-in-human trials in five years, hoping this new therapy will eschew the ...

Whole-mount 3D imaging at the cellular scale is a powerful tool for exploring complex processes during morphogenesis. In organoids, it allows examining tissue architecture, cell types, and morphology ...